RxDoctor Payments Data

Hilary Bluedorn

Nurse Practitioner · New Wilmington, PANPI 1174375844

Payments from drug & device makers

$2,800in general payments, 2019–2025

Across 133 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$308
  • AstraZeneca$288
  • Exact Sciences$287
  • Boehringer Ingelheim$240
  • AbbVie$235
  • Amphastar Pharmaceuticals, Inc.$215
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,74098%
  • Education$602%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,800 in reported general payments places this provider in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$25,242
Medicare patients
115
Services billed
381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin33$7,750
EliquisApixaban29$7,580
Fentanyl15$1,082
Potassium Chloride84$640
Alprazolam56$558
Divalproex Sodium12$552
Carbidopa-LevodopaCarbidopa/Levodopa30$409
Fluticasone Propionate26$404
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen17$371
Sertraline Hcl19$335
Bumetanide16$277
Furosemide70$252
Lorazepam37$251
Oxycodone Hcl20$251
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen15$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$240$7,75033 claims
PfizerEliquis$198$7,58029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in New Wilmington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →